Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression

Cyndi R. Morales, Dan L. Li, Zully Pedrozo, Herman I. May, Nan Jiang, Viktoriia Kyrychenko, Geoffrey W. Cho, Soo Young Kim, Zhao Wang, David Rotter, Beverly A Rothermel, Jay W Schneider, Sergio Lavandero, Thomas G. Gillette, Joseph A Hill

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Altering chromatin structure through histone posttranslational modifications has emerged as a key driver of transcriptional responses in cells. Modulation of these transcriptional responses by pharmacological inhibition of class I histone deacetylases (HDACs), a group of chromatin remodeling enzymes, has been successful in blocking the growth of some cancer cell types. These inhibitors also attenuate the pathogenesis of pathological cardiac remodeling by blunting and even reversing pathological hypertrophy. The mechanistic target of rapamycin (mTOR) is a critical sensor and regulator of cell growth that, as part of mTOR complex 1 (mTORC1), drives changes in protein synthesis and metabolism in both pathological and physiological hypertrophy. We demonstrated through pharmacological and genetic methods that inhibition of class I HDACs suppressed pathological cardiac hypertrophy through inhibition of mTOR activity. Mice genetically silenced for HDAC1 and HDAC2 had a reduced hypertrophic response to thoracic aortic constriction (TAC) and showed reduced mTOR activity. We determined that the abundance of tuberous sclerosis complex 2 (TSC2), an mTOR inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class IHDACs were inhibited. In neonatal rat cardiomyocytes, loss of TSC2 abolished HDAC-dependent inhibition of mTOR activity, and increased expression of TSC2 was sufficient to reduce hypertrophy in response to phenylephrine. These findings point to mTOR and TSC2-dependent control of mTOR as critical components of the mechanism by which HDAC inhibitors blunt pathological cardiac growth. These results also suggest a strategy to modulate mTOR activity and facilitate the translational exploitation of HDAC inhibitors in heart disease.

Original languageEnglish (US)
Article numberra34
JournalScience Signaling
Volume9
Issue number422
DOIs
StatePublished - Apr 5 2016

Fingerprint

Tuberous Sclerosis
Histone Deacetylases
Cardiomegaly
Sirolimus
Hypertrophy
Cardiac Myocytes
Chromatin
Histone Code
Growth
Pharmacology
Chromatin Assembly and Disassembly
Tuberous Sclerosis 2
Cell growth
Phenylephrine
Post Translational Protein Processing
Metabolism
Constriction
Histones
Rats
Heart Diseases

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. / Morales, Cyndi R.; Li, Dan L.; Pedrozo, Zully; May, Herman I.; Jiang, Nan; Kyrychenko, Viktoriia; Cho, Geoffrey W.; Kim, Soo Young; Wang, Zhao; Rotter, David; Rothermel, Beverly A; Schneider, Jay W; Lavandero, Sergio; Gillette, Thomas G.; Hill, Joseph A.

In: Science Signaling, Vol. 9, No. 422, ra34, 05.04.2016.

Research output: Contribution to journalArticle

Morales, CR, Li, DL, Pedrozo, Z, May, HI, Jiang, N, Kyrychenko, V, Cho, GW, Kim, SY, Wang, Z, Rotter, D, Rothermel, BA, Schneider, JW, Lavandero, S, Gillette, TG & Hill, JA 2016, 'Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression', Science Signaling, vol. 9, no. 422, ra34. https://doi.org/10.1126/scisignal.aad5736
Morales, Cyndi R. ; Li, Dan L. ; Pedrozo, Zully ; May, Herman I. ; Jiang, Nan ; Kyrychenko, Viktoriia ; Cho, Geoffrey W. ; Kim, Soo Young ; Wang, Zhao ; Rotter, David ; Rothermel, Beverly A ; Schneider, Jay W ; Lavandero, Sergio ; Gillette, Thomas G. ; Hill, Joseph A. / Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. In: Science Signaling. 2016 ; Vol. 9, No. 422.
@article{481f912a12ed41c2827e47cfa875af5d,
title = "Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression",
abstract = "Altering chromatin structure through histone posttranslational modifications has emerged as a key driver of transcriptional responses in cells. Modulation of these transcriptional responses by pharmacological inhibition of class I histone deacetylases (HDACs), a group of chromatin remodeling enzymes, has been successful in blocking the growth of some cancer cell types. These inhibitors also attenuate the pathogenesis of pathological cardiac remodeling by blunting and even reversing pathological hypertrophy. The mechanistic target of rapamycin (mTOR) is a critical sensor and regulator of cell growth that, as part of mTOR complex 1 (mTORC1), drives changes in protein synthesis and metabolism in both pathological and physiological hypertrophy. We demonstrated through pharmacological and genetic methods that inhibition of class I HDACs suppressed pathological cardiac hypertrophy through inhibition of mTOR activity. Mice genetically silenced for HDAC1 and HDAC2 had a reduced hypertrophic response to thoracic aortic constriction (TAC) and showed reduced mTOR activity. We determined that the abundance of tuberous sclerosis complex 2 (TSC2), an mTOR inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class IHDACs were inhibited. In neonatal rat cardiomyocytes, loss of TSC2 abolished HDAC-dependent inhibition of mTOR activity, and increased expression of TSC2 was sufficient to reduce hypertrophy in response to phenylephrine. These findings point to mTOR and TSC2-dependent control of mTOR as critical components of the mechanism by which HDAC inhibitors blunt pathological cardiac growth. These results also suggest a strategy to modulate mTOR activity and facilitate the translational exploitation of HDAC inhibitors in heart disease.",
author = "Morales, {Cyndi R.} and Li, {Dan L.} and Zully Pedrozo and May, {Herman I.} and Nan Jiang and Viktoriia Kyrychenko and Cho, {Geoffrey W.} and Kim, {Soo Young} and Zhao Wang and David Rotter and Rothermel, {Beverly A} and Schneider, {Jay W} and Sergio Lavandero and Gillette, {Thomas G.} and Hill, {Joseph A}",
year = "2016",
month = "4",
day = "5",
doi = "10.1126/scisignal.aad5736",
language = "English (US)",
volume = "9",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "422",

}

TY - JOUR

T1 - Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression

AU - Morales, Cyndi R.

AU - Li, Dan L.

AU - Pedrozo, Zully

AU - May, Herman I.

AU - Jiang, Nan

AU - Kyrychenko, Viktoriia

AU - Cho, Geoffrey W.

AU - Kim, Soo Young

AU - Wang, Zhao

AU - Rotter, David

AU - Rothermel, Beverly A

AU - Schneider, Jay W

AU - Lavandero, Sergio

AU - Gillette, Thomas G.

AU - Hill, Joseph A

PY - 2016/4/5

Y1 - 2016/4/5

N2 - Altering chromatin structure through histone posttranslational modifications has emerged as a key driver of transcriptional responses in cells. Modulation of these transcriptional responses by pharmacological inhibition of class I histone deacetylases (HDACs), a group of chromatin remodeling enzymes, has been successful in blocking the growth of some cancer cell types. These inhibitors also attenuate the pathogenesis of pathological cardiac remodeling by blunting and even reversing pathological hypertrophy. The mechanistic target of rapamycin (mTOR) is a critical sensor and regulator of cell growth that, as part of mTOR complex 1 (mTORC1), drives changes in protein synthesis and metabolism in both pathological and physiological hypertrophy. We demonstrated through pharmacological and genetic methods that inhibition of class I HDACs suppressed pathological cardiac hypertrophy through inhibition of mTOR activity. Mice genetically silenced for HDAC1 and HDAC2 had a reduced hypertrophic response to thoracic aortic constriction (TAC) and showed reduced mTOR activity. We determined that the abundance of tuberous sclerosis complex 2 (TSC2), an mTOR inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class IHDACs were inhibited. In neonatal rat cardiomyocytes, loss of TSC2 abolished HDAC-dependent inhibition of mTOR activity, and increased expression of TSC2 was sufficient to reduce hypertrophy in response to phenylephrine. These findings point to mTOR and TSC2-dependent control of mTOR as critical components of the mechanism by which HDAC inhibitors blunt pathological cardiac growth. These results also suggest a strategy to modulate mTOR activity and facilitate the translational exploitation of HDAC inhibitors in heart disease.

AB - Altering chromatin structure through histone posttranslational modifications has emerged as a key driver of transcriptional responses in cells. Modulation of these transcriptional responses by pharmacological inhibition of class I histone deacetylases (HDACs), a group of chromatin remodeling enzymes, has been successful in blocking the growth of some cancer cell types. These inhibitors also attenuate the pathogenesis of pathological cardiac remodeling by blunting and even reversing pathological hypertrophy. The mechanistic target of rapamycin (mTOR) is a critical sensor and regulator of cell growth that, as part of mTOR complex 1 (mTORC1), drives changes in protein synthesis and metabolism in both pathological and physiological hypertrophy. We demonstrated through pharmacological and genetic methods that inhibition of class I HDACs suppressed pathological cardiac hypertrophy through inhibition of mTOR activity. Mice genetically silenced for HDAC1 and HDAC2 had a reduced hypertrophic response to thoracic aortic constriction (TAC) and showed reduced mTOR activity. We determined that the abundance of tuberous sclerosis complex 2 (TSC2), an mTOR inhibitor, was increased through a transcriptional mechanism in cardiomyocytes when class IHDACs were inhibited. In neonatal rat cardiomyocytes, loss of TSC2 abolished HDAC-dependent inhibition of mTOR activity, and increased expression of TSC2 was sufficient to reduce hypertrophy in response to phenylephrine. These findings point to mTOR and TSC2-dependent control of mTOR as critical components of the mechanism by which HDAC inhibitors blunt pathological cardiac growth. These results also suggest a strategy to modulate mTOR activity and facilitate the translational exploitation of HDAC inhibitors in heart disease.

UR - http://www.scopus.com/inward/record.url?scp=84963612261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963612261&partnerID=8YFLogxK

U2 - 10.1126/scisignal.aad5736

DO - 10.1126/scisignal.aad5736

M3 - Article

C2 - 27048565

AN - SCOPUS:84963612261

VL - 9

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 422

M1 - ra34

ER -